Inhibiting 5‐lipoxygenase prevents skeletal muscle atrophy by targeting organogenesis signalling and insulin‐like growth factor‐1
Abstract Background Skeletal muscle atrophy can occur in response to numerous factors, such as ageing and certain medications, and produces a major socio‐economic burden. At present, there are no approved drugs for treating skeletal muscle atrophy. Arachidonate 5‐lipoxygenase (Alox5) is a drug targe...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2022-12-01
|
| Col·lecció: | Journal of Cachexia, Sarcopenia and Muscle |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/jcsm.13092 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|